Peter A. Fasching, n/a

University Hospital Erlangen
Comprehensive Cancer Center Erlangen-EMN, Bavarian Cancer Research Center (BZKF), Erlangen, Germany, United States

Presentation(s):

• 2: Phase 3 study of neoadjuvant pembrolizumab or placebo + chemotherapy, followed by adjuvant pembrolizumab or placebo plus endocrine therapy for early-stage high-risk ER+/HER2− breast cancer: KEYNOTE-756

  Friday, March 22, 2024
  1:14pm – 1:26pm ET